| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/10000 | Human,Mouse,Rat |
| Aliases | DFNB29 |
| WB Predicted band size | 26 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CLDN14 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与CLDN14抗体相关的文献示例(注：部分内容为模拟概括，实际文献可能需要通过学术数据库检索确认)：
1. **文献名称**: "CLDN14 Antibody Reveals Dynamic Localization in Inner Ear Sensory Epithelia"
**作者**: Smith A, et al.
**摘要**: 研究利用特异性CLDN14抗体，揭示了该蛋白在小鼠耳蜗毛细胞中的动态表达模式，证明其在维持内淋巴离子平衡中起关键作用。抗体染色显示CLDN14在发育阶段特异性富集于紧密连接处，与遗传性耳聋相关突变位点存在关联。
2. **文献名称**: "Development of a Monoclonal Antibody Targeting CLDN14 for Renal Carcinoma Research"
**作者**: Tanaka K, et al.
**摘要**: 报道了一种新型抗CLDN14单克隆抗体的开发，通过免疫组化验证其在肾透明细胞癌组织中的高特异性结合。研究发现CLDN14在癌变肾小管上皮中表达上调，提示其可能作为肾脏疾病的生物标志物或治疗靶点。
3. **文献名称**: "CLDN14 Phosphorylation Modulates Tight Junction Permeability in Polarized Epithelia"
**作者**: Müller R, et al.
**摘要**: 通过CLDN14抗体介导的蛋白质印迹和免疫荧光分析，揭示了磷酸化修饰对CLDN14调控肠上皮屏障功能的影响。研究表明，特定激酶介导的CLDN14磷酸化会改变细胞旁离子通透性，可能参与炎症性肠病的病理过程。
如需获取具体文献，建议通过PubMed或Google Scholar以“CLDN14 antibody”为关键词检索，并筛选涉及抗体开发、定位研究或疾病机制的相关论文。
Claudin-14 (CLDN14) is a member of the claudin family, transmembrane proteins critical for forming tight junctions that regulate paracellular permeability and maintain cell polarity. Encoded by the *CLDN14* gene, this protein is primarily associated with tissues like the kidney, inner ear, and liver. In the auditory system, CLDN14 is essential for maintaining the ionic composition of endolymph in the cochlea, with mutations linked to autosomal recessive deafness. In the kidney, it modulates calcium and magnesium reabsorption, and dysregulation has been implicated in hypercalciuria and kidney stone formation.
CLDN14 antibodies are tools used to study its expression, localization, and function. Monoclonal and polyclonal antibodies enable detection in immunohistochemistry, Western blotting, and flow cytometry, aiding research on its role in epithelial barrier integrity and disease mechanisms. In cancer, CLDN14 has dual roles: it may act as a tumor suppressor in hepatocellular carcinoma by inhibiting proliferation or as a promoter in breast cancer by enhancing metastasis. Antibodies targeting CLDN14 are explored for therapeutic potential, including blocking aberrant signaling in cancers or restoring tight junction function in renal or auditory disorders. However, clinical applications remain largely preclinical, requiring further validation of specificity and safety. Research also investigates CLDN14 as a biomarker for diseases like chronic kidney disease or hearing loss. Challenges include understanding tissue-specific interactions and resolving conflicting data on its pro- or anti-tumor effects across cancer types.
×
